Expanding the use of hepatitis C-viremic kidney donors.

Published

Journal Article

Direct-acting antivirals have revolutionized the treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease, with implications for the timing of antiviral treatment among kidney transplant candidates and for the use of HCV viremic donors. A recent consensus conference reviewed the available data on the safety and cost-effectiveness of expanding access to HCV-positive organs to HCV-negative recipients. Early trials are promising, but larger trials and a plan for obtaining HCV therapy in the posttransplantation period are needed. Implications for the larger transplant community also need to be considered.

Full Text

Duke Authors

Cited Authors

  • Sawinski, D; Wyatt, CM; Locke, JE

Published Date

  • November 2017

Published In

Volume / Issue

  • 92 / 5

Start / End Page

  • 1031 - 1033

PubMed ID

  • 29055420

Pubmed Central ID

  • 29055420

Electronic International Standard Serial Number (EISSN)

  • 1523-1755

Digital Object Identifier (DOI)

  • 10.1016/j.kint.2017.09.002

Language

  • eng

Conference Location

  • United States